Live Geos: https://partners.subjectwell.com/publishers/geos_report/c13fca96-1459-4cba-bf75-26d7053e161f **ALL COPY AND CREATIVE (OUTSIDE OF WHICH IS IN OUR CREATIVE FOLDER) NEEDS TO BE SUBMITTED TO [email protected] PRIOR TO GOING LIVE FOR APPROVAL** Ages: 12-17 Study Description: This study is testing an investigational injectable medication for atopic dermatitis (eczema). Participants will receive an injection of either the study medication or placebo once every 4 weeks for a period lasting 6 to 9 months. Additional procedures include physical exams, blood tests, and questionnaires. Total participation will last between 9 to 12 months and would include 12-13 doctor’s visits throughout the study. Eligibility for the study will be determined by the study doctor following one or more in-person screening visits to the clinic. Trial-related procedures and study medication will be provided at no cost. Qualifications: - Child must be diagnosed with eczema for one year or longer - Eczema must cover 10% of their body or more - Child should have tried any of the following treatments: Injectable medications, including Dupixent (dupilumab) or Adbry (tralokinumab) - Oral tablets such as Rinvoq (Upadacitinib), Cibinqo (Abrocitinib), or Olumiant (Baricitinib -Topical skin creams such as Crisaborole, Hydrocortisone, Clobetasol, Tacrolimus or Pimecrolimus. - Previous medications should not have worked or had caused side effects that made them stop taking them

ClicksAdv, LLC